126 results about "Artificial tears" patented technology

A system and method are provided for measuring the thickness of a tear film layer and the heights of tear menisci around upper and lower eyelids of an eye. A plurality of images are acquired between consecutive blinks the eye using optical coherence tomography (OCT). The images depict the tear film layer and tear menisci as distinct from the cornea of the eye. In an embodiment, a plurality of reflectivity profiles from an OCT image are aligned and averaged. The difference between a first peak and a second peak of the average reflectivity profile is measured to determine the thickness of the tear film layer. The heights of the upper meniscus and the lower meniscus can also be measured from the same OCT image. In an embodiment, thickness measurements from the plurality of OCT images are combined. The measurements can be used to diagnose tear disorders, analyze treatments of dry eye and evaluate artificial tears.

Methods and devices measure eye blinks and tear film lipid and aqueous layer thickness before and following ophthalmic formula application onto the ocular surface, especially wherein the ophthalmic formula is an artificial tear. The methods and devices are suitable for dry eye diagnosis. The methods and devices are suitable for use to evaluate ophthalmic formula effects on the tear film and to use such information to diagnose ophthalmic formula treatment of ocular disease conditions such as dry eye in the absence of contact lens wear or post-surgical eye drop treatment and diagnosis. The methods and devices are also suitable for use in the optimization of ophthalmic drug dosage forms and sustained drug release.

A tear replacement solution that contains at least one water-soluble fluorosurfactant, water and a non-polar component, preferably in gel form, and a method for the external treatment for the eye of an mammal by applying the tear replacement solution to the eye, preferably by placing in the conjunctival sac.

The lacrimal implant delivery systems and methods described herein provide for controlled release of a therapeutic agent for the treatment of disease, including the treatment of glaucoma, ocular hypertension, or elevated intraocular pressure with latanoprost or other anti-glaucoma agents. Treatment of disease, including glaucoma, ocular hypertension, or elevated intraocular pressure with latanoprost or other anti-glaucoma agent in conjunction with penetration enhancer, such as benzalkonium chloride, and/or artificial tears is also provided. Also provided are implants containing a drug core emplacable in a punctum adjacent to an eye of a patient for controlled release of a therapeutic agent such as latanoprost for the treatment of glaucoma, the drug core containing a polymer such as cross-linked silicone, a therapeutic agent, and an excipient, wherein the excipient can increase the rate of release of the agent from the drug core, or can increase the drug loading in the core without loss of desirable homogeneity of the agent within the core, or can improve retention of the agent in the eye or in tear fluid, or can increase corneal penetration of the agent into the eye.

Methods and devices measure eye blinks and tear film lipid and aqueous layer thickness before and following ophthalmic formula application onto the ocular surface, especially wherein the ophthalmic formula is an artificial tear. The methods and devices are suitable for dry eye diagnosis. The methods and devices are suitable for use to evaluate ophthalmic formula effects on the tear film and to use such information to diagnose ophthalmic formula treatment of ocular disease conditions such as dry eye in the absence of contact lens wear or post-surgical eye drop treatment and diagnosis. The methods and devices are also suitable for use in the optimization of ophthalmic drug dosage forms and sustained drug release.

A formulation has been developed for treatment of the symptoms of dry eye which incorporates the natural product jojoba wax, or components thereof, to enhance the spreading of the artificial tear and eyedrop as well as stabilize the eyedrop. The improved performance of the jojoba wax supplemented tear relieves irritation and discomfort as well as sharpens the blurred vision.

The ophthalmic drug delivery vehicles provide comfort and compliance; drug solubility, residence time and permeability; and reduce side effects. In addition, the delivery vehicle can be slightly modified to provide an artificial tear formulation.

The invention provides artificial tear compositions, artificial tear-gel compositions, contact lens storage compositions, contact lens treatment compositions, ophthalmological drug vehicle compositions and topical drug vehicle compositions comprising one or more nonionic surfactants with one or more non-Newtonian viscosity enhancing excipients and one or more of a polyol and or an electrolyte and methods of their use.

The invention provides artificial tear compositions comprising one or more nonionic surfactants with one or more non-Newtonian viscosity enhancing excipients.

This invention relates to an emulsion composition for the formation of an artificial tear film over the ocular surface of the eye capable of providing mechanical lubrication for the ocular surface while reducing evaporation of fluid therefrom. The emulsion is desirably in the form of a meta stable emulsion and is characterized by the use of a surfactant comprising a combination of a primary and secondary surfactant where the primary surfactant permits formation of the emulsion and the secondary surfactant permits autoclaving of the surfactant. The invention also includes a method for the formation of such an emulsion.

The present invention relates to artificial tear compositions and ophthalmic compositions suitable for drug delivery. In one embodiment of the present invention, the compositions comprise a galactomannan polymer such as guar or hydroxypropyl guar, hyaluronic acid, and a cis-diol such as sorbitol. In a preferred embodiment, the compositions also comprise a borate compound.

Topical ophthalmic compositions that form a gel or partial gel upon application to the eye are described. The compositions are particularly useful as artificial tears and ocular lubricants, but may also be utilized for the topical delivery of pharmaceutically active compounds to the eye. The compositions contain a polysaccharide/borate gelling system. The polysaccharides that may be utilized contain cis-diol groups and have a structure that is predominately linear, with a slight degree of branching.

The invention provides artificial tear compositions comprising one or more nonionic surfactants with one or more non-Newtonian viscosity enhancing excipients.

The present invention relates to a vitamin A liposome artificial tears eye drops for preventing and curing xerophthalmia and ophthalmokopia. Its composition includes fat-soluble vitamin A, liposome encapsulating material, vitamin E and artificial tears hydrated liquor, in which the fat-soluble vitamin A is vitamin A palmitate or vitamin A acetate, the liposome encapsulating material is soya bean lecithin and cholesterol, and the composition of artificial tears hydrated liquor includes sodium hydrogen carbonate, sodium chloride, glucose, potassium chloride, calcium chloride and water. Besides, according to requirements one or several kinds of auxiliary components of menthanol, PVP and HPMC, etc. also can be added.

An ophthalmic composition for artificial tears useful for treating dry eye symptoms or for general eye protection. The composition includes a physiologically balanced salt solution and one or more anti-oxidative ingredients which collectively confer on said ophthalmic composition a total antioxidant capacity as a FRAP value of greater than 100 μmol/l, preferably greater than 150 μmol/l. The composition also has peak UV absorption in the range of 200-350 nm. Suitable anti-oxidative ingredient includes ascorbate (ascorbic acid), urate (uric acid), cysteine, glutathione, tyrosine, lactoferrin, transferrin, albumin, caeruloplasmin and lacrimal gland peroxidase.

The invention relates to artificial tear containing trehalose and the preparation and application method, which pertains to the technical field of pharmaceutical manufacture. The main component of the invention is the trehalose, the basic composition of the artificial tear is the trehalose, simulating mucin protein and conventional ophthalmic pharmaceutical excipients; the weight ratio of the three is that 0.3 to 97 percent trehalose, 0.3 to 97 percent simulating mucin protein and 2 to 98 percent conventional ophthalmic pharmaceutical excipients. The pH and the osmotic pressure of the artificial tear of the invention are equivalent to physiologic tear, the invention contains rich electrolyte ions, the type and the content of the ions are equivalent to the physiologic tear, and the invention can be used in the treatment of dry eye syndrome and the adjuvant treatment of diseases which are caused by other dry eye syndromes. At the same time, the invention can be used as the drug delivery system of various ophthalmic drugs.

The invention relates to artificial tears, in particular to artificial tears including carnosine, concretely, the artificial tears including carnosine comprise the following components and contents in percentage by weight: 0.2-5.0 percent of carnosine, an osmotic pressure regulator, a pH regulator and the balance of water, wherein the osmotic pressure regulator makes the mill-osmotic pressure mol concentration ratio of the artificial tears be between 0.9 and 1.1, and the pH regulator makes the pH value of the artificial tears be between 5.0 and 9.0. The artificial tears including carnosine can be used for treating dry eye syndrome, and also has a function of preventing cataract. The invention also relates to a preparation method of the artificial tears.

The invention relates to an eye formulation administering system containing lecithin and sodium hyaluronic acid and its preparing method, wherein the system can directly serve as artificial tears to be applied to the treatment of xerophthalmia and other ophthalmology diseases. The system may also include other active constituents.

The present invention uses sodium hyaluronate and polyvinyl pyrrolidone together to produce synergistic action and prepare said invented eye-moistening solution composition which possesses the effects of moistening eye region, making artificial tears, raising exchange of tears and lubricating soft contact lens to raise wearing comfort.